No abstract available
Keywords:
central nervous system; ibrutinib; lymphoma.
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Brain / pathology
-
Central Nervous System Neoplasms / diagnosis
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / secondary*
-
Humans
-
Lymphoma, Mantle-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / pathology*
-
Magnetic Resonance Imaging / methods
-
Male
-
Middle Aged
-
Multicenter Studies as Topic
-
Piperidines
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Recurrence
-
Retreatment
-
Treatment Outcome
-
Vereinigtes Königreich
Substances
-
Antineoplastic Agents
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
ibrutinib
-
Adenine